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Abstract 
Extracellular vesicles (EVs) are emerging as a promising alternative approach to cell-
therapies. However, to realise the potential of these nanoparticles as new regenerative tools, 
healthcare materials that address the current limitations of systemic administration need to be 
developed. Here, two technologies for controlling the structure of alginate based microgel 
suspensions were used to develop sustained local release of EVs, in vitro. Microparticles 
formed using a shearing technique were compared to those manufactured using vibrational 
technology, resulting in either anisotropic sheet-like or spheroid particles, respectively. EVs 
harvested from pre-osteoblasts were isolated using differential ultracentrifugation and 
successfully loaded into the two systems, whilst maintaining their structures. Promisingly, in 
addition to exhibiting even EV distribution and high stability, controlled release of vesicles from 
both structures was exhibited, in vitro, over the 12 days studied. Interestingly, a significantly 
greater number of EVs were released from the suspensions formed by shearing (69.9±10.5%), 
compared to the spheroids (35.1±7.6%). Ultimately, alterations to the hydrogel physical 
structures have shown to tailor nanoparticle release whilst simultaneously providing ideal 
material characteristics for clinical injection. Thus, the sustained release mechanisms 
achieved through manipulating the formation of such biomaterials, provide a key to unlocking 
the therapeutic potential held within EVs.  
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1 Introduction 
Extracellular vesicles (EVs) are biological nanoparticles with lipid bilayers comprising of 
cytoplasmic and membrane proteins as well as nucleic acids, including mRNA and miRNA.[1] 
EVs are released from most cell types under physiological as well as pathological conditions 
and can be categorised into three subtypes: exosomes, microvesicles (or shedding vesicles), 
and apoptotic bodies.[2, 3] These subgroups are distinguished by size, biogenesis, and to some 
extent by their protein markers. The release of exosomes (30 - 150 nm) into the extracellular 
environment occurs through the endocytic pathway, while microvesicles (100 - 1000 nm) are 
generated by outward budding or blebbing from the cell’s plasma membrane. Finally, apoptotic 
bodies with broad size range (100 - 5000 nm) are released from dying cells and contain 
multiple, densely packed, organelles.[1, 2, 4] 
 
EVs have been shown to have roles in cell-cell interactions and important biological processes 
such as immunomodulation, cancer progression, angiogenesis, and tissue regeneration.[5, 6] 
More specifically, the effective role of vesicles derived from mineralising osteoblasts and 
mesenchymal stem cells has been demonstrated for bone regeneration and regulation of 
osteogenesis.[7, 8] The repair of bone defects remains a huge demand within modern medicine. 
The possibility of stimulating osteoblasts in vitro to produce vesicles programmed to promote 
osteogenesis, or other regenerative processes, when delivered locally to the site of a defect 
presents an exciting new approach to solving this growing challenge. One of the great potential 
advantages of the therapeutic application of cell-derived vesicles is that this technology may 
overcome some of the complications associated with cell-based therapies, including malignant 
stem cell transformation, and nutrient as well as oxygen deprivation at the recipient site, which 
can significantly affect cell survival rates.[9-11] Another strength of the therapeutic application 
of EVs is their potential to be generated in vitro under defined conditions. If this could be 
achieved at scale, then this may present significant economic and regulatory advantages 
compared with the use of stem cells.  
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There are, however, currently two major obstacles for the therapeutic application of vesicles. 
Firstly, scaling at a reproducible and cost-effective level is still unfounded, restricted by large-
scale isolation in sufficient quantities of ‘active’ vesicles.[5, 12] The second obstacle is targeting 
EVs to a specific therapeutic location and maintaining an efficacious dose at that site so that 
localised pathologies, such as bone diseases or tumours, may be treated. Previous studies 
have demonstrated rapid uptake of vesicles by organs, such as the lungs and liver due to 
aggregation and recognition by the reticuloendothelial system. In vivo studies for monitoring 
the distribution of systematically administered cell-derived vesicles based on the application 
of fluorescent imaging techniques, fails to prove targeted delivery of these effective 
nanoparticles to specific tissues.[9, 12-15] As such, the incorporation of vesicles into delivery 
devices for the treatment of localised pathologies presents the opportunity for controlled 
release thus overcoming the issues with systemic administration. Additionally, the 
development of such systems may prove advantageous on multiple fronts including, delivery 
of nano-therapies within the field of cancer treatment [16], reduction in dosages through 
enhanced bioavailability and unlocking the potential of EVs for the tissue engineering and 
biomaterials communities. 
 
The use of injectable synthetic or natural polymeric biomaterials present opportunities to tailor 
release by altering physicochemical properties.[17] Specifically, alginate, a polysaccharide with 
the ability to undergo gelation in situ, has gained much interest in recent years within drug 
delivery and regenerative medicine.[18-21] Alginate’s ability to undergo gelation in situ arises 
through its chemical structure, with repeating blocks of mannuronic and guluronic acid 
residues resulting in an “egg-box” gelation mechanism; divalent crosslinking of homopolymeric 
regions of guluronic acid residues, using Ca2+ ions.[22] Recently, much attention has been 
given to restructuring hydrogel matrices, with a view to manipulating the microstructure and 
subsequent bulk properties, including release of various biomolecules.[23]  As such, processing 
technologies such as applying shear have been employed to ultimately confine the gelation 
process, restricting gel formation to result in suspensions of microparticles. Bulk properties 
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(viscosity, moduli, etc.) have been shown to be a function of the gelation kinetics; whereby an 
equilibrium between polymerisation and shear breakdown results in weak inter-particle 
interactions, forming weak gel-like networks at rest that flow under applied deformation.[24] In 
these cases, entrapment is achieved via several mechanisms: firstly, becoming trapped within 
the gelled phases and/or, secondly, becoming trapped within the interstitial regions between 
particles. In comparison, encapsulation technologies, such as vibrational nozzle, form droplets 
by forcing an alginate sol through an orifice, leading to entrapment of moieties solely within 
the gel due to rapid curing. Release of these trapped molecules is governed by factors such 
as polymer concentration and crosslink density.[25]  
 
This research seeks to control EV release kinetics in a sustained manner with the potential to 
facilitate local delivery for the treatment of contained pathologies. In this paper we compare 
two processing methods that result in different degrees of EV confinement by employing either 
shear or vibration to form micro-particulate suspensions with varying intrinsic properties. To 
assess the suitability of these different systems for localised EV release this paper covers: (1) 
manufacture and characterisation of the microgel suspensions as a minimally invasive delivery 
system; (2) evaluation of vesicle stability through processing and cytotoxicity; and (3) a 
comparison of the in vitro release of vesicles from the two structured systems. Notably, the 
EV population used in this study was isolated from osteoblasts grown under osteogenic 
conditions, which have been previously demonstrated to exhibit the capacity to induce stem 
cell mineralisation beyond that of the current gold standard treatment (bone morphogenetic 
protein-2 (BMP-2)).[7] Therefore, to the best of our knowledge, this is the first attempt to use 
biomaterials to control the local release of regenerative cell-derived vesicles. Overall, this 
paper highlights the promise for cell-derived vesicles to be utilised as biological, but acellular, 
regenerative tools that could be employed to treat a range of local pathologies, including 
cancer and musculoskeletal defects. 
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2 Materials and methods 
 
2.1 Cell culture 
MC3T3 pre-osteoblasts (ATCC CRL-2593, UK; passage number < 10) were cultured in 
Minimum Essential Medium (alpha-MEM; Sigma, UK) supplemented with 10% fetal bovine 
serum (FBS; Sigma, UK), 2 mM L-glutamine (Sigma, UK), and 1% penicillin/streptomycin 
(Sigma, UK). All cultures were incubated at 37°C with 5% CO2 until they reached 70-80% 
confluence. Culture medium was changed every other day to enhance cell growth and viability.  
2.2 EV isolation 
MC3T3s were expanded in T-175 cm2 flasks in osteogenic medium, which was prepared by 
the addition of 50 µg/mL L-ascorbic acid (Sigma, UK) and 10 mM ß-glycerophosphate (Sigma, 
UK) to exosome-depleted growth medium. For the preparation of osteogenic medium, 
exosome-depleted FBS was prepared by ultra-centrifuging the serum for 16h at 120,000 g.[7] 
Cells were grown for two weeks, and osteoblast-derived EVs isolated from the conditioned 
culture medium using a differential ultracentrifugation method. Briefly, the conditioned media 
was centrifuged at 2,000 g for 20 min to remove cell debris. The supernatant was then 
centrifuged at 10,000 g for 30 min, followed by ultra-centrifugation (Sorvall WX Ultra Series; 
Thermo Fisher, UK) (Rotor: Fiberlite, F50L-8 × 39 fixed-angle rotor; Piramoon Technologies 
Inc., USA) at 120,000 g for 70 min. For further purification, the pellet was washed in sterile 
filtered phosphate buffer saline (PBS; Sigma, UK) at 120,000 g for 70 min.[7, 26] All 
centrifugation steps were performed at 4°C. The pellet was then re-suspended in 200 µL of 
PBS and stored at -20°C.  
 
2.3 EV characterisation 
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Since the focus of this work is the polymeric systems, readers are directed to previous work 
that provides a full characterisation of the EVs used in this study, including proteomics. [10] 
However, since the purity of EVs is important within the field and to adhere with the minimal 
experimental requirements recommended by Lotvall et al. 2014, Western blots have been 
performed along with two techniques to characterise single vesicles; transmission electron 
microscopy (TEM) and nanoparticle tracking analysis (NTA).[27]  
Western blotting analysis was used to confirm the presence of EV proteins. Following 
electrophoretic separation using precast 4-15% Mini-PROTEAN® TGX™ gels (Biorad), the 
gels were blotted onto PVDF membranes (Invitrogen) and blocked with 5% non-fat milk 
powder (Alix, Annexin A2 and TSG1010) or 2% non-fat milk powder (CD63) in Tris-buffered 
saline. After 1 hour blocking at room temperature, the membranes were incubated with 
primary antibodies in their respective blocking buffers overnight at 4°C at a dilution of 1:1000 
(Alix, Annexin A2 and TSG1010) and 1:500 (CD63) in Tris-buffered saline containing 0.5% 
Triton X 100. After three washes, the blots were incubated with 1:2000 horseradish 
peroxidase-conjugated secondary antibodies for 1 hour at room temperature. 
Chemiluminescence detection of bands was performed with ECL Plus reagent (Biorad).   
TEM was performed using negative staining for which 5 μl of EV sample was absorbed on a 
continuous carbon-coated copper grid (Agar Scientific). Then the sample was stained with 
UranyLess EM (CN Technical Services, Ltd.) followed by lead citrate (CN Technical Services, 
Ltd.). All the steps were performed on drops of a parafilm. The grids were left to dry before 
being visualised on a JEOL 2100, 200 kV LaB6 TEM. Micrographs were acquired in RADIUS 
2.0 (Build 14402) software using a MegaView G3 (Olympus Soft Imaging Solutions) camera 
at a resolution of 1776 x 1456. 
Vesicles suspended in PBS were analysed by NTA using the Nanosight LM10 (Malvern 
Instruments Ltd, UK) utilising a 455 nm laser. Based on Brownian motion, EV size and 
concentration was calculated using accompanying software (version 3.2). For all samples, 
ambient temperature was set to 22°C and camera level and detection threshold were adjusted 
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between 12-15 and 3-7, respectively. For each sample, five videos of 30 second duration were 
recorded. The number of completed tracks per sample was > 500. 
 
2.4 Preparation of encapsulation solutions 
Medium viscosity alginate (ALG; ≥20,000 cP, M/G ratio=1.56) from brown algae (Sigma, UK) 
was used to manufacture microgel suspensions. 1% and 2% w/v alginate solutions were 
prepared in sterile deionised water while the solution was heated to 90°C under stirred 
conditions for two hours. Cross-linking solutions (0.1 and 0.2 M) were prepared by dissolving 
granular calcium chloride (Sigma, UK) in deionised water. All solutions were sterile filtered 
using 0.22 µm syringe filter (Millipore, USA) and left under a UV light overnight. 
 
2.5 Preparation of alginate microgel suspension 
A range of sheared microgel suspensions with formulations obtained through design of 
experiments were produced as detailed in Table 1. An overhead stirrer equipped with pitch 
blade impeller was used to provide the shear field required for the formation of the sheared 
microgel suspensions (fig. 2b). The cross-linker (CaCl2) was slowly added to the alginate sol 
at the impeller tip, in order to form the hydrogel particles within the turbulent regime. After the 
addition of the cross-linker, systems were further mixed for 10 min, and then degassed using 
a sonicator for 15 min to remove any trapped air. The entire gelation process was performed 
at room temperature, and each formulation was made in duplicate to assess reproducibility. 
All fluid gels were stored at 4°C for 24h before being used for rheological studies. 
Encapsulation of EVs was undertaken at room temperature by suspending EVs (5.6 x109 
particles/ml) in the alginate solution prior to crosslinking. 
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Table 1: Design of experiments to assess the effect of alginate concentration, cross-linker 
concentration, the volumetric ratio between the polymer and the cross-linker, and the magnitude of 
shear field on microgel suspension rheology 
Alginate 
Concentration (%w/v) 
CaCl2 
Concentration (M) 
CaCl2 / Alginate 
(%v/v) 
Agitator 
Speed (RPM) 
1 0.1 7.5 300 
1 0.1 15 300 
2 0.1 6 300 
2 0.1 9 300 
2 0.1 12 300 
1 0.2 6 300 
2 0.2 4 300 
2 0.2 6 300 
2 0.2 9 1200 
2 0.2 8 1200 
2 0.2 6 1200 
 
2.6 Preparation of alginate spheroidal microparticles 
EVs at a concentration of 5.6 x109 particles/mL were suspended in sterile 1%w/v alginate 
solution. The microparticles were generated using a vibrational nozzle encapsulator (A B-395 
pro, Buchi, UK) under sterile conditions.[25] The generated droplets were incubated in a 
crosslinking solution (0.1 M CaCl2) located at 20 cm from the nozzle head for 10 min (fig. 2c). 
The encapsulator parameters were: nozzle inner diameter = 200 µm, frequency = 6000 Hz, 
electrode = 1200 V, and pump flow rate = 40 mL/min. The generated spheroidal microparticles 
were then filtered and subjected to several washes with PBS to remove any remaining 
unbound calcium ions. The size distribution of 20 randomly selected alginate microparticles 
were then determined using a light microscope (Olympus Co., Germany) and Image J 
software (NIH, Bethesda, MD, USA).   
2.7 Rheological characterisation 
Manufactured alginate sheared microgel suspensions were evaluated using an AR-1000 
rheometer (TA Instruments, UK) fitted with a stainless-steel cone and plate geometry (cone 
angle of 2 ° and diameter of 40 mm). An oscillatory sweep (frequency sweep), and flow curve 
(viscosity versus shear rate) at a constant temperature of 37 °C were performed. Small 
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deformation rheology was undertaken by varying the frequency applied to the gel (0.01 to 10 
Hz) at a constant strain determined to be within the linear viscoelastic region (0.5%). Dynamic 
viscosity measurements were conducted between 0.1 to 1000 s-1 in rate controlled mode. A 
toothpaste sample was used as a positive control for this study since this product exhibits 
controllable flow behaviour and desirable recovery characteristics following application of 
shear stress. Furthermore, the use of a readily available product presents the opportunity for 
others in the field to easily conduct comparative studies.  
2.8 Live/dead assay 
The cytocompatibility of the optimised sheared microgel suspension composition was 
examined using a live/dead cytotoxicity assay (Invitrogen, UK). Briefly, MC3T3s (2x105 
cells/mL) were seeded on the top of transwell plate (fig. 4).  After 4h of incubation, the sheared 
microgel suspension was placed on the top of the transwell insert (pore size: 0.4 µm) and cells 
were incubated at 37 °C for 48 h. On the day of the experiment 5 µL of calcein AM (live cell 
marker; Ex: 495 nm; Em: 515 nm) and 25 µL of propidium iodide (PI; dead cell marker; Ex: 
488 nm; Em: 617 nm) were added to 2 mL of growth medium (alpha-MEM supplemented with 
10% v/v foetal bovine serum).[28] Cells were then incubated in the dark at 37 °C for 15 min. 
Stained cells were visualised using confocal laser scanning microscopy (Olympus FV1000, 
Multiple Ar laser, Germany). For the control, the viability of cells without gel was examined. 
2.9 Labelling of EVs with fluorescent dyes 
To investigate the integrity of vesicles during sheared microgel suspension formation, isolated 
EVs were stained with two fluorescent dyes. The lipid membrane and RNA cargo of EVs were 
stained using FM1-43FX [29, 30] (Ex: 479 nm; Em: 598 nm), and SYTO RNA Select (Ex: 488 
nm; Em: 530 nm), respectively according to the manufacturer’s instructions (Life technology, 
UK). Briefly, prior to encapsulation, EVs were stained with the RNA dye at a final concentration 
of 10 µM and incubated at 37 °C for 20 min. Labelled EVs were then washed twice in PBS 
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using ultracentrifugation at 120,000 g for 70 min. For the lipid dye, the EVs were stained with 
a final dye concentration of 5 µg/mL. The stained EVs were incubated at room temperature 
for 10 min and were then washed in PBS. A confocal microscope was used to visualise 
fluorescently-labelled samples at 10x magnification. Reconstruction of raw z-stack images of 
3D gels were achieved using Imaris software (Bitmap, UK). Further studies were performed 
by measuring the amount of co-localisation between the two dyes using Image J (coloc.2 
plugin). Numerical data were evaluated by Pearson's correlation coefficient (R-value) for 
which a value of 1 represents a perfect linear correlation and values above 0.7 indicate a 
strong correlation.[31, 32] To obtain accurate co-localisation results, acquired micrographs had 
low noise level, and the same point spread function was applied for both green and red 
channels. Additionally, for evaluating the number of encapsulated EVs within focal planes of 
the alginate sheared microgel suspension and microparticles a spot-detector plugin from 
Imaris software was employed. 
2.10 Release studies from alginate systems 
In vitro release profiles of EVs from both alginate structures were carried out by direct 
dispersion method.[33, 34] Loaded alginate sheared microgel suspensions and microparticles 
were each suspended in 2 mL of sterile filtered PBS and incubated at 37 °C. The receiving 
medium was sampled (300 µL) from each system at regular time intervals and was 
immediately replaced by an equal amount of fresh PBS. The collected samples were then 
assayed to quantify EV release. 
For the short-term release studies (1, 3, and 5 h), the concentration of released particles in 
the receiving medium was measured using NTA. This analysis was used as an initial indication 
of any release and to compare size profiles with those of EVs before incorporation into the 
alginate systems. To ascertain whether particles detected by NTA were in fact EVs, an 
ExoELISA-ULTRA complete kit was used to assay the media from long-term release studies 
(1, 3, 6, and 12 days). This further analysis indicated the concentration of CD63 positive 
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particles, a known EV surface marker, that were released from the systems which were 
compared with NTA results. The cumulative percentage released from hydrogels at each time 
point was determined by considering the dilution effect, and all experiments were performed 
in duplicate. Further, for both assays control samples of void spheroid microparticles and 
microgel suspension were also evaluated and no release was detected by via NTA or 
ExoELISA.  
2.11 Statistical analysis 
Graphs and statistical analyses were performed using Prism-7 software (Graph Pad, San 
Diego, CA). Results are presented as the mean ± standard error of the mean (SEM). One-
way analysis of variance (ANOVA) was used to identify any significant difference between the 
means of independent groups. Furthermore, a Bonferroni post-hoc test was performed with 
ANOVA to find means that were significantly different between groups. A p-value < 0.05 was 
considered as significant. 
 
3 Results 
3.1 Characterisation of osteoblast derived EVs 
Despite the focus on this manuscript being the release of EVs from injectable biomaterials, it 
was important to first demonstrate purity. Characterisation was conducted following guidelines 
published by the International Society for Extracellular Vesicles.[27] Western blots confirmed 
the presence of ISEV designated markers, Alix (97 KDa), CD63 (50-60 KDa), TSG101 (45-50 
KDa) and Annexin A2 (37 KDa) (fig 1a). A typical spheroid morphology was demonstrated 
using TEM (fig 1b) with an average size of 186±4 nm confirmed by NTA (fig 1 c). Based on 
the size of isolated vesicles they are non-specifically referred to as extracellular vesicles, 
which demonstrates a mixed population, likely consisting of exosomes and micro vesicles. It 
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is also notable that micrographs of these osteoblast derived EVs revealed a relatively high 
electron density, as was confirmed previously by our team.[7]  
 
 
Fig 1. Characterisation of EVs. (a) Western blot analysis of common EV markers (Alix, Annexin A2, 
TSG101 and CD63). A total of 5 µg of protein was loaded for Alix, Annexin A2 and TSG101. 20 µg of 
protein was loaded for CD63. (b) Micrographs demonstrating typical spheroidal morphology of EV 
population (left) and electron density of single vesicle (right). (c) Particle size distribution of EV sample 
extracted from nanoparticle tracking analysis (NTA) indicating an average size of 186±4 nm. 
 
3.2 Formulation and characterisation of EV loaded microgel suspensions 
3.2.1 Microparticle size, shape and EV distribution 
Light microscopy was used to evaluate both particle size and shape following either shear or 
vibration processing. Figure 2 shows the change in particle morphologies as a function of the 
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confinement technique used during the sol-gel transition, with sheared systems forming large 
anisotropic particles (fig. 2a) and vibrational systems exhibiting spheroidal shape (fig. 2b). The 
alginate micro-particles generated using vibrational technology exhibited a high degree of 
homogeneity, with an average diameter of 364 ± 6 µm. However, irregular shape and 
distribution of particles made it difficult to size the sheared systems in this way.  
In order to investigate the distribution of the encapsulated EVs within the two microgel 
suspensions, the lipid membrane of EVs were stained with a fluorescent dye (FM1-43FX) 
before encapsulating. Confocal microscopy demonstrated an even distribution of EVs within 
both alginate systems (fig. 2c). In the case of the spheroids, EVs were distributed throughout 
the particles only. In contrast, for the sheared systems, EVs were evenly observed across the 
whole volume studied, irrespective of particle shape and distribution. Quantitative evaluation 
of 3D reconstructed micrographs revealed an average of 1226 ± 21 and 1114 ± 53 EVs per 
1000 µm for the sheared and spheroidal micro-particles, respectively. Thus, confirming that 
the number of EVs incorporated in both physically structured systems were similar. Some 
aggregation of EVs was found to occur in both sheared and spheroids, which is not remarkable 
given their size. Notably, no fluorescent signal was detected in control samples without EVs 
(this image is not shown since it was entirely black).  
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Fig 2. Schematic representation the manufacturing process for both EV loaded systems, 
highlighting the resultant structures. (a) Manufacturing set-up for an alginate microgel suspension 
(2%w/v alginate, 0.2 M CaCl2, and 6% v/v) and resulting physical structure. (b) Production of spheroid 
alginate microparticles using vibrational technology (nozzle inner diameter: 200 µm, frequency: 6000 
Hz, electrode: 1200 v, pump flow rate: 40 mL/min) and images highlighting final homogeneous gel 
structure. (c) 3D visualisation of encapsulated vesicles within the sheared microgel suspension and 
spheroid microparticles; vesicles were labelled with FM1-43FX before encapsulation; scale bars show 
100 µm (particles radius scale: 2) 
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3.2.2 Rheological characterisation and injectability  
It is important to recognise that processing parameters play an important role in resultant 
particle diameters, distribution and shape,[35] factors which all ultimately influence the clinical 
applicability and release kinetics of loaded actives. For spheroid microparticles formed via the 
vibration method the alginate concentration, flow rate and vibrational frequency were 
optimised such that the solution jet broke up into uniform droplets (364 ± 6 µm). 
In the case of the sheared systems, multiple formulations and process parameters were 
investigated in order to assess any influence on key rheological properties (fig. 3). All of the 
manufactured samples were found to exhibit shear-thinning behaviour (fig. 3a). Application of 
a higher agitator speed (1200 rpm) during processing, as well as increased polymer (2% w/v) 
and cross-linker (0.2 M) concentrations, resulted in a shift in flow profiles towards that of the 
positive control, toothpaste. 
Following these initial findings, the viscoelasticity of two compositions, containing different 
ratios of polymer to crosslinker (8% vCaCl2/vALG and 6% vCaCl2/vALG), was assessed. Small 
deformation rheology was conducted over a range of frequencies (from 0.1 to 10 Hz), at a 
constant physiological temperature, in order to probe gel-like behaviours at rest - post-
injection. Figure 3b shows the mechanical data obtained for both storage modulus (G’) and 
loss modulus (G”) as a function of frequency, for both sheared systems in comparison to the 
control. Sheared systems displayed a small degree of frequency dependency, typically lying 
between a strong and weak gel. Such observations are commonly noted for such systems as 
interactions between the particles give rise to a weak elastic network.[36] Suspensions 
formulated with a lower salt to polymer ratio, 6% vCaCl2/vALG, exhibited lower G’ and G’’ values, 
more similar to the control. The injectability data also demonstrated that the sheared systems 
with 6% vCaCl2/vALG were easier to inject, as indicated by an overall lower maximum force (3.8 
N versus 4.3 N) experienced during extrusion (fig. 3c). Therefore, based on rheological 
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studies, the sheared microgel suspension with 2% w/v alginate, 0.2 M CaCl2, and 6% v/v was 
further investigated for the encapsulation/release of osteoblast-derived vesicles. 
 
Fig 3. Rheological characterisation of alginate sheared microgel suspensions at 37 °C. (a) 
Viscosity profiles for the sheared microgel suspensions processed at both 300 rpm and 1200 rpm 
stirrer speeds. (b) Frequency sweeps obtained at 0.5% strain dependence, closed markers denote 
storage modulus (G’) and open, loss modulus (G’’). (c) Injectability data showing the force required to 
expel the formulations through a 21G needle 
 
3.3 EV stability throughout processing and microgel cytotoxicity 
3.3.1 Evaluation of lipid membrane and RNA co-localisation for encapsulated 
vesicles 
The degree of co-localisation of fluorescently labelled membrane lipid and RNA cargo was 
investigated as a tool to assess if the EVs were intact post-encapsulation. Statistical analysis 
of confocal micrographs confirmed a high degree of co-localisation between the two dyes, as 
indicated by an R-value greater than 0.7 (R = 0.819 ± 0.06), suggesting the EV cargo and 
membrane were largely still associated following processing. Images in Figure 4 are from the 
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sheared microgel suspensions and similar trends were observed for the spheroidal 
microparticles (not shown). Again, some aggregation of EVs were witnessed.  
 
Fig 4. Visualisation of fluorescently stained vesicles utilising confocal scanning microscopy. 
Co-localisation analysis: encapsulated vesicles following incubation with RNA probe (SYTO RNA 
Select, green channel) and lipid dye (FM1-43FX, red channel); scale bars show 50 µm. 
 
3.3.2 Microgel cytotoxicity  
To determine whether the optimised sheared alginate microgel suspension had any adverse 
effect on cell viability, MC3T3 pre-osteoblasts were cultured in the presence and absence of 
the formulation. Confocal images acquired after 48h revealed a similar degree of cell viability 
between the control and those exposed to the sheared microgel suspension (fig. 5). The 
results suggest that cell viability remained close to 100% for both groups.  
 
 
Fig 5. Visualisation of microgel cytocompatibility utilising fluorescence. Two-dimensional 
confocal micrograph of live pre-osteogenic cells (MC3T3s) in contact with optimised alginate sheared 
microgel suspension formulation (2% ALG, 0.2 CaCl2, 6 %v/v) using transwell plate culturing method 
(calcein AM marker: green channel); scale bars show 100 µm. 
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3.4 EV release from microgel suspensions 
All in vitro release studies were performed in PBS at pH=7.2. Short-term release studies, up 
to 5 hours (fig. 6a), were conducted using NTA to assay elution media for particles. After 1, 3, 
and 5h, cumulative releases of 9.3±1.1%, 18.62±3.8%, and 22.7±2.9% was measured, 
respectively, from the sheared system, demonstrating a gradual release during the first few 
hours (fig. 6a). For the alginate spheroids, after 5h the cumulative release was found to be 
only 2.2±0.3% (fig. 6a).  
 
Fig 6. Evaluation of vesicles release from alginate sheared versus spheroidal microparticles. 
(a) Short and (b) long term cumulative release profiles for vesicles in PBS. (c) Statistical comparison 
between the average size (nm) of intact and vesicles released from both the sheared microgel 
systems. (d) Size distribution of intact (non-encapsulated) vesicles determined by nanoparticles 
tracking analysis (NTA) (Note, this data is also represented in fig 1c but repeated here to enable 
direct comparison). (e) and (f) Average histogram plotted with NTA reports representing size 
distribution of released vesicles from sheared and spheroidal microparticles over 1h, 3h, and 5h. Error 
bars show ± SEM. (g) Mean and median diameter (d50) of both non-encapsulated and encapsulated 
vesicles obtained from NTA. 
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Longer-term release studies (up to 12 days) were determined based on CD63 antigens, a 
tetraspanin protein known to be associated with the membrane of cell-derived vesicles. Figure 
6b shows that 27.42±1.6% of CD63 positive EVs were released from the sheared alginate 
system after 24h, increasing to 69.88±10.5% over the following 12 days. Notably, a lower 
cumulative release of 13.87±6% after 24h (p= 0.081) and 35.10±7.55% after 12 days 
(p=0.015) was observed from the alginate spheroids (fig. 6b). This trend was in agreement 
with results obtained from short-term release studies. 
 
Interestingly, Figure 6c demonstrates statistically significant differences between the average 
size of freshly isolated EVs (fig. 1c/6d), and particles released from the developed systems at 
each time point. Despite the different hydrogel structures, no statistical difference (p > 0.05) 
between the average size of released EVs from sheared microgel suspensions and spheroidal 
particles were detectable (fig. 6c). Although, notably at 5 hrs there appeared to be a greater 
portion of EVs >300 nm eluted from the sheared microgels, suggesting that diffusion of larger 
aggregates was hindered in the spheroid networks (fig. 6e and f).  
4 Discussion 
Over the last decade, cell-derived EVs have been shown to play a critical role in cellular 
communication and tissue regeneration. To date, systemic delivery of EVs has been the only 
method studied for the administration of isolated vesicles within biological systems.[37, 38] 
However, in vivo studies have demonstrated that upon systemic delivery, EVs are 
sequestered within the first 30 min after injection by circulating macrophages mainly in the 
liver, spleen, kidneys, and lungs. Hence, strategies to achieve localised release of EVs may 
enable their promising therapeutic potential to be realised. Notably, there is significant 
literature that highlights local administration of nanoparticles at the therapeutic site may 
improve efficacy,[9, 38, 39] which presumably is extendable to EVs. The present study 
demonstrates for the first time the possibility to manipulate the physical structure of a popular 
biocompatible hydrogel, alginate, to produce injectable systems capable of releasing cell-
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derived vesicles. We show that by altering the physical structure of the polymer, by applying 
two different processing techniques, it is possible to tailor the release of EVs in an in vitro 
model. While in this paper we have loaded these systems with EVs isolated from pre-
osteoblast cells there would certainly be opportunities to incorporate vesicles derived from 
other cell types or even synthetic nanoparticles for the treatment of different pathologies, such 
as cancer.  
 
Shearing during the sol-gel transition as a means to confine gelation into microparticles was 
compared to those formed using vibrational nozzle technology, an approach more commonly 
adopted in the literature. This resulted in very different suspension microstructures, with 
anisotropic and spheroidal homogeneous microparticles formed on shear and vibration, 
respectively. Particles in both cases were observed to be less than 700 µm (364 ± 6 µm in the 
case of spheroids), complying with injectable systems previously described for pharmaceutical 
reagents or cells.[41] Notably, particles produced using the vibrational nozzle technique 
resulted in narrow size distributions, compared with other microencapsulation techniques.[26, 
42, 43] In our previous study, it was verified that a combination of experimental parameters, such 
as polymer flow rate, frequency, and polymer concentration can influence the average 
diameter, size distribution and shape of the produced microparticles, which can be 
manipulated to achieve a desired profile.[25] Here, we aimed for small particles to facilitate 
injection through smaller syringe needles, and provide a greater surface area to volume ratio 
for the diffusion of encapsulated vesicles into the surrounding environment.  
 
Following manufacture of both alginate systems, it was important to determine the distribution 
of the EVs within the hydrogel matrices. Due to the small size of EVs imaging is reportedly 
difficult, as the nano-sized particles constantly moving under Brownian motion. However, in 
this study, the gelled structures provided a matrix which suppressed EV motion. As such, 
images were able to be taken over extended period, allowing 3D z-stacks to be obtained. 3D 
reconstructions (fig. 2c) highlighted homogenous distributions of the EVs across both microgel 
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systems, where, in the case of the spheroids restriction to the gelled phase can clearly be 
seen. In contrast, sheared systems exhibited uniform distributions indiscriminate of the gelled 
or surrounding aqueous phase. Such changes arise from the processing; where using 
vibration technology, rapid gelation as the drops enter the curing vat prevents diffusion of EVs 
into the aqueous phase at this time. However, imparting shear during the sol-gel transition 
inevitably causes some of the EVs to remain outside the gelled phase, becoming subsequently 
trapped between particles. In addition to using these hydrogels as a means to control EV 
release, immobilisation of nanoparticles within these systems may also facilitate imaging 
approaches.[40] 
 
Taking the clinical application into consideration, minimally invasive techniques are 
advantageous due to their patient compliance. Release of EVs from a locally injected gel 
would be more acceptable to potential patients compared with more invasive open 
procedures. Injections, present a good way of locally delivering biomaterials that may release 
therapeutics. In order to guide what rheological behaviour would be desirable for an injectable 
therapeutic agent, we chose to use toothpaste as a positive control. This is because it is readily 
available, and exhibits shear thinning behaviour that enables easy injection (fig. 3). As such, 
a commercially available injectable product, toothpaste, was selected for baseline in which to 
compare material behaviours. Rheological characterisation under physiological conditions (pH 
= 7.2 and temperature 37°C) revealed that all formulations exhibited shear-thinning behaviour 
(fig. 3a). Such behaviour is desirable within injectable systems, lowering the magnitude of 
force required to administer the therapy. Furthermore, sheared systems showed weak solid-
like viscoelastic characteristics at rest (fig. 3b). Again, such properties make it ideal for 
sustained release, providing a structure that remains stable post-injection without falling apart. 
Together the material behaviour allows the system to act like a liquid through the needle and 
then self-structuring in situ to provide a gel for controlled localised delivery. The 2%w/v 
alginate, 0.2 M CaCl2 (6% v/v mixture) was found to give mechanical data closest to the ideal 
control, on this basis it was selected for further studies.  
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Processing conditions are key when designing delivery devices for sensitive therapeutics. 
During the manufacture and encapsulation processes, EVs are exposed to a high degree of 
mixing, and resultant shear forces. Thus, it is critical to evaluate the stability of EVs in the form 
of retained biological structure post-process. Promisingly, a high degree of co-localisation 
between the lipid membrane and internal RNA content (R-value: 0.819 ± 0.06) (fig. 4) was 
observed. This data along with detection of CD63+ particles in long-term release studies (fig. 
6b) is promising evidence that EV integrity is maintained following processing and release. 
Notably, it will be important that future studies confirm efficacy of the released biomolecules. 
In relation to this, it is notable that the entire encapsulation process can be completed in less 
than 10 min under sterile conditions. This short encapsulation process as well as relatively 
mild processing conditions, are beneficial for encapsulation of bioactives such as EVs, which 
are sensitive to both temperature and pH changes. Cytotoxic effects of the microgels were 
studied using pre-osteoblasts (MC3T3s), cultured in the presence of the systems for 48hrs. 
Data showed no effect of the microgels on cell survival (fig. 5). Retention of EV structure and 
lack of toxicity demonstrated the alginate systems to be potential candidates for real clinical 
applications. However, understanding the kinetics behind release is required for a sustained 
application.  
 
A comparison in release profiles between the two distinctly structured forms of alginate 
revealed a notable difference in kinetics. For both systems, no initial burst was observed post 
in vitro immersion. Such observations arise through the uniform distribution of EVs through 
the matrices (fig 2); as burst release from hydrogels is mainly associated with molecules being 
embedded in the outer surfaces and payloads escaping during manufacture.[41, 42]  Interestingly 
NTA analysis of elution media (fig. 6c-g) demonstrated that the particles detected were slightly 
larger, with a longer tail in the distribution on the higher diameter end, than the average initial 
EV size that was incorporated into both systems. Since no release was detected from control 
samples of void spheroid microparticles and microgel suspensions, it is hypothesised that the 
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released particles detected by NTA may be a mixture of single or aggregated EVs that may 
exit with a small amount of the alginate or that charge groups within the alginate affect the 
microparticle sizes. Notably, the particles released and the size of encapsulated EVs are 
larger than the pore-size threshold for alginate gels.[43] As such, ready or rapid release was 
not expected and this was confirmed in the short-term release study (fig 6a). Since both the 
EV membrane and alginate molecules are negatively charged, it is unlikely that any 
electrostatic interactions between the two species has occurred. It is therefore suggested that 
small pockets of EVs become trapped by the polymer not used during the gelation process. 
However, it is important to note that future work should look to assess any interaction between 
the hydrogel structure and vesicle membrane to confirm if any polymer residue is present. 
Notably, based on NTA results the encapsulation efficiency of the EVs was 95% in the sheared 
microgel suspension and 99% within the spheroidal microparticles.  
 
To confirm if any of the particles detected by NTA were in fact EVs, an EXO-ELISA was used 
for the longer-term release study to assay for a vesicle specific protein marker. This analysis 
demonstrated that there was a cumulative increase in CD63 present in the elution media of 
both the sheared and spheroidal systems, confirming EVs were being released from both 
hydrogel structures. Interestingly, kinetics for the sheared systems were almost twice as fast 
as the spheroids. This likely arises from the physical structuring because, on quantitative 
evaluation of confocal micrographs, similar numbers of EVs were initially present. For the 
spheroids, EVs are fully encapsulated in the cross-linked alginate and need to diffuse through 
the pores of the network; whereas in comparison, since the vesicles are incorporated into both 
the particles and surrounding aqueous phase, migration through the weakly interacting 
sheared microgel is more easily achieved. This provides an additional method to control 
release in conjunction to the previously reported methods for hydrogels: swelling/pore size of 
the network, any affinity interactions between the bioactive agent and the carrier, and any 
degradation of the gel.[44, 45] Therefore, such behaviours clearly indicate the potential of the 
25 
 
unique microstructure, to balance effective release of nano-sized therapies whilst engineering 
in desired rheological characteristics.  
 
This study demonstrates that the existence of these two levels of structuring, 1) the formation 
of particles via crosslinking of polymers and 2) weak interactions between particles, within the 
sheared microgel suspensions enhances the release of EVs. Extending this application 
further, it is presumed that other anionic nano-sized molecules, such as anticancer drugs 
could take advantage of the sustained release it provides.[46] Furthermore, the nature of these 
systems also presents the opportunity to increase the degree of control over release, tailoring 
the proportion of particles incorporated either in or between gelled entities. It is worth 
mentioning that vesicles are nanoparticles with a negative surface charge, which is due to the 
structure of their lipid membrane. Therefore, the release profile achieved here might not be 
applicable for positively charged moieties. 
5 Conclusions 
Two injectable polymeric systems with different physical structures were systemically 
investigated for local release of cell-derived extracellular vesicles; with particular emphasis on 
clinically relevant parameters such as application (injectability), bio-stability/toxicity and 
release. The integrity of vesicles incorporated into the manufacture of systems via sheared 
and vibrating nozzle technologies were confirmed using a co-localisation study. Promisingly, 
even and stable distributions of EVs within both alginate suspensions eliminated burst release, 
over the initial short-term in vitro assays (up to 5h). More specifically, the multi-level structuring 
achieved by shearing the hydrogel during gelation resulted in interactions between anisotropic 
particles that exhibited desirable rheological properties (shear thinning and solid-like 
structures at rest) whilst also enabling sustained release over 12 days. Notably, the technique 
used to form the microgel particles ultimately dictated the microstructure and resultant release 
kinetics, with the spheroidal systems releasing a significantly lower concentration of EVs.  
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While osteoblast-derived vesicles were used as a model in this study, the various properties 
achievable by applying shear during gelation could also be exploited to deliver other 
biomolecules with similar size/chemical profiles. In summary, this work highlights the vast 
potential of physically manipulating biomaterials to enable controlled release of extracellular 
vesicles, which presents a new approach in regenerative medicine. Future in vivo studies will 
be needed to confirm the bioactivity of released vesicles, as well as evaluating appropriate 
dosages. 
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